Nuclear export dysfunction due to increased expression/activity of CRM1 is a hallmark shared by HGPS and different types of cancer (García‐Aguirre et al. 2019; Mahipal and Malafa 2016); however, pharmacological inhibition of CRM1 mediated by selinexor has different physiological consequences in each cell system. Here, XPO1 is linked to cancer.